Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Immunology Letters|February 23, 2010
Long-term "in vitro" proliferating mouse hematopoietic progenitor cell linesPatricia Vegh, Jana Winckler, Fritz Melchers
The Journal of Antimicrobial Chemotherapy|May 14, 2019
Pharmacokinetics of adjusted-dose 8-hourly lopinavir/ritonavir in HIV-infected children co-treated with rifampicinHelena Rabie, Holly Rawizza, Peter Zuidewind, et al.
The Pediatric Infectious Disease Journal|September 14, 2022
Hepatocellular Injury in Children Treated for Rifampicin-resistant Tuberculosis: Incidence, Etiology and OutcomeJoanie Duvenhage, Heather R Draper, Anthony J Garcia-Prats, et al.
Plos Medicine|May 1, 2019
Pharmacokinetics, optimal dosing, and safety of linezolid in children with multidrug-resistant tuberculosis: Combined data from two prospective observational studiesAnthony J Garcia-Prats, H Simon Schaaf, Heather R Draper, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 23, 2018
Clinical and Cardiac Safety of Long-term Levofloxacin in Children Treated for Multidrug-resistant TuberculosisAnthony J Garcia-Prats, Heather R Draper, Heather Finlayson, et al.
Antimicrobial Agents and Chemotherapy|November 15, 2017
Pharmacokinetics and Drug-Drug Interactions of Lopinavir-Ritonavir Administered with First- and Second-Line Antituberculosis Drugs in HIV-Infected Children Treated for Multidrug-Resistant TuberculosisLouvina E van der Laan, Anthony J Garcia-Prats, H Simon Schaaf, et al.
Antimicrobial Agents and Chemotherapy|November 15, 2017
Levofloxacin Population Pharmacokinetics in South African Children Treated for Multidrug-Resistant TuberculosisPaolo Denti, Anthony J Garcia-Prats, Heather R Draper, et al.
Antimicrobial Agents and Chemotherapy|December 19, 2023
Pharmacokinetics and cardiac safety of clofazimine in children with rifampicin-resistant tuberculosisAli Mohamed Ali, Belén P Solans, Anneke C Hesseling, et al.
Antimicrobial Agents and Chemotherapy|June 26, 2023
QT Interval Prolongation with One or More QT-Prolonging Agents Used as Part of a Multidrug Regimen for Rifampicin-Resistant Tuberculosis Treatment: Findings from Two Pediatric StudiesAli Mohamed Ali, Kendra K Radtke, Anneke C Hesseling, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 19, 2021
Optimizing Dosing and Fixed-Dose Combinations of Rifampicin, Isoniazid, and Pyrazinamide in Pediatric Patients With Tuberculosis: A Prospective Population Pharmacokinetic StudyPaolo Denti, Roeland E Wasmann, Annelies van Rie, et al.
Pageof 2